Table 1 Clinical characteristics of AML patients
Patients Parameters | All Patients (n = 101) | BRAF expression | P | |
|---|---|---|---|---|
High (n = 45) | Low (n = 56) | |||
Sex, male/female | 49/52 | 20/25 | 29/27 | 0.5344 |
Median age, year, (range) | 48.71 (15–80) | 52.58 (20–80) | 45.63 (15–79) | 0.0377 |
Median WBCx109/L, (range) | 45.07 (0.82–496.28) | 50.84 (0.95–396.28) | 40.46 (0.82–496.28) | 0.5412 |
Median HGB, g/L, (range) | 81.02 (25–159) | 80.25 (41–136) | 81.64 (25–159) | 0.7899 |
Median PLTx109/L, (range) | 70.10 (2–866) | 68.61 (2–479) | 71.31 (6–866) | 0.9036 |
FAB classification | ||||
M1 | 3 (2.97%) | 2 (4.44%) | 1 (1.79%) | |
M2 | 28 (27.72%) | 11 (24.44%) | 17 (30.36%) | |
M3 | 6 (5.94%) | 4 (8.89%) | 2 (3.57%) | |
M4 | 13 (12.87%) | 8 (17.78%) | 5 (8.93%) | |
M5 | 26 (25.74%) | 8 (17.78%) | 18 (32.14%) | |
M6 | / | / | / | |
M7 | / | / | / | |
Others | 15 (14.85%) | 8 (17.78%) | 7 (12.50%) | |
sAML | 10 (9.90%) | 4 (8.89%) | 6 (10.71%) | |
Karyotypes | ||||
Abnormal karyotypes | 21 (20.79%) | 11 (24.44%) | 10 (17.86%) | 0.5658 |
Gene mutation | ||||
WT1 | 29 (28.71%) | 13 (28.89%) | 16 (28.57%) | 0.9724 |
NPM1 | 9 (8.91%) | 8 (17.78%) | 1 (1.79%) | 0.0047 |
DNMT3A | 9 (8.91%) | 5 (11.11%) | 4 (7.14%) | 0.4915 |
FLT3-ITD | 12 (11.88%) | 8 (17.78%) | 4 (7.14%) | 0.1026 |
FLT3-TKD | 4 (3.96%) | 4 (8.89%) | / | 0.0227 |
FLT3 | 2 (1.98%) | 1 (2.22%) | 1 (1.79%) | 0.8772 |
AML-ETO | 5 (4.95%) | 2 (4.44%) | 3 (5.36%) | 0.8356 |
TET2 | 5 (4.95%) | 2 (4.44%) | 3 (5.36%) | 0.8356 |
C-KIT | 5 (4.95%) | 2 (4.44%) | 3 (5.36%) | 0.8356 |
IDH1 | 4 (3.96%) | 3 (6.52%) | 1 (1.79%) | 0.2152 |
IDH2 | 3 (2.97%) | 3 (6.52%) | / | 0.0505 |
SRSF2 | 3 (2.97%) | 1 (2.22%) | 2 (3.57%) | 0.6949 |
NRAS | 3 (2.97%) | / | 3 (5.36%) | 0.1173 |
TP53 | 2 (1.98%) | 1 (2.22%) | 1 (1.79%) | 0.8772 |
RUNX1 | 2 (1.98%) | / | 2 (3.57%) | 0.2042 |
ASXL1 | 2 (1.98%) | / | 2 (3.57%) | 0.2042 |
SF3B1 | 2 (1.98%) | / | 2 (3.57%) | 0.2042 |
Risk category | 0.002 | |||
Favorable | 2 (1.98%) | / | 2 (3.57%) | |
Intermediate | 90 (89.11%) | 41 (91.11%) | 49 (87.50%) | |
Adverse | 9 (8.91%) | 4 (8.89%) | 5 (8.93%) | |
Treatment regimen | 0.001 | |||
Chemotherapy-only | 80 (79.21%) | 40 (88.89%) | 40 (71.43%) | |
HSCT | 21 (20.79%) | 5 (11.11%) | 16 (28.57%) | |